Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.
|Original language||English (US)|
|Number of pages||9|
|State||Published - 2003|
Bibliographical noteFunding Information:
This research was supported by grants from the Dutch Cancer Society (to A.W. Griffioen), the Department of Defense DA/DAMD 17-99-1-9564 (to K.H. Mayo) and the National Institutes of Health R01 CA-96090 (to K.H. Mayo).
- Angiogenesis inhibition
- Angiostatic peptides
- Angiostatic proteins
- Designer peptides and review